Palatin Technologies, Inc. PTN was a big mover last session, as the company saw its shares rise nearly 6% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This breaks the recent trend of the company, as the stock is now trading above the volatile price range of 96 cents to $1.01 in the past one-month time frame.
The move came after the company reported positive results of oral clinical study of PL-8177 for several inflammatory bowel diseases.
The company has seen no estimate revisions over the past few weeks, while the Zacks Consensus Estimate for the current quarter remained unchanged. The recent price action is encouraging though, so make sure to keep a close watch on this firm in the near future.
Palatin Technologies currently has a Zacks Rank #3 (Hold) while its Earnings ESP is 0.00%.
Palatin Technologies, Inc. Price
Palatin Technologies, Inc. Price | Palatin Technologies, Inc. Quote
A better-ranked stock in the Medical - Biomedical and Genetics industry is ANI Pharmaceuticals, Inc. ANIP, which currently carries a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Is PTN going up? Or down? Predict to see what others think: Up or Down
Zacks' Top 10 Stocks for 2019
In addition to the stocks discussed above, would you like to know about our 10 finest buy-and-holds for the year?
Who wouldn't? Our annual Top 10s have beaten the market with amazing regularity. In 2018, while the market dropped -5.2%, the portfolio scored well into double-digits overall with individual stocks rising as high as +61.5%. And from 2012-2017, while the market boomed +126.3, Zacks' Top 10s reached an even more sensational +181.9%.
See Latest Stocks Today >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
ANI Pharmaceuticals, Inc. (ANIP) : Free Stock Analysis Report
Palatin Technologies, Inc. (PTN) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research